(MENAFN- Market Press Release) October 14, 2025 2:58 am - The Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market, valued at $2,485 million in 2025, is projected to reach $3.5 billion by 2032 at a 5% CAGR.

Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market Poised to Reach $3.5 Billion by 2032, Driven by Rising Heart Failure Cases

The global Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market, valued at $2,485 million in 2025, is projected to grow at a 5% CAGR between 2025 and 2032, reaching approximately $3.5 billion by 2032. This steady expansion is supported by the increasing prevalence of cardiovascular diseases, improved diagnosis rates, and growing adoption of advanced heart failure therapies across major healthcare markets.

Improved healthcare infrastructure in North America and Europe, along with rapid drug uptake in Asia-Pacific, is boosting overall market value. Government reimbursement support, rising clinical awareness, and the expansion of specialty pharmaceutical distribution channels further accelerate adoption. Countries such as the United States, Germany, Japan, and India are emerging as key revenue contributors due to high patient pools and expanding access to branded cardiovascular drugs.

Segment Focus: Heart Failure and Hypertension Lead Adoption

The primary application segment driving ARNIs demand is chronic heart failure management, where these drugs are increasingly prescribed to reduce hospitalization and mortality risks. Hypertension treatment protocols are also beginning to integrate ARNIs in high-risk patient groups. Additionally, hospital pharmacy and specialty clinic distribution channels are witnessing growing prescription volumes due to enhanced physician awareness and guideline updates favoring combination therapy.

Price Trend: Stable Growth with Regional Variations

In 2024, the average treatment cost per patient in the United States stood slightly lower due to competitive pricing strategies, while Germany and Japan experienced a 2–3% price increase in 2025, driven by regulatory adjustments and currency fluctuations. Despite pricing pressures in some Asian markets, improved reimbursement coverage in public healthcare systems is stabilizing price volatility and supporting consistent patient access.

Key Players Reshaping Market Dynamics

Leading pharmaceutical companies dominating the ARNI landscape include Novartis (Europe/Global), which holds a significant share with its flagship therapy, followed by AstraZeneca and Pfizer (North America) supporting pipeline innovation. In Asia, companies like Daiichi Sankyo and Takeda Pharmaceuticals are enhancing regional market penetration through strategic collaborations and localized distribution. These players are focusing on label expansion, clinical trials, and regional partnerships to strengthen their market position across emerging economies.

Request for customization

MENAFN15102025003520003262ID1110198011